Azerbaijan vs Republic of Moldova: The number of people with susceptibility test result for rifampicin
Azerbaijan
96.11
in 2021
Republic of Moldova
96.4
in 2021
Azerbaijan rank
47th
Republic of Moldova rank
44th
The number of people with susceptibility test result for rifampicin over time
- Azerbaijan
- Republic of Moldova
How they compare
Republic of Moldova currently reports 96.4 against 96.11 in Azerbaijan, a difference of 0.29.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Azerbaijan ahead.
Azerbaijan ranks 47th and Republic of Moldova ranks 44th of 146 countries.
Across the 2 decades both report, Azerbaijan averaged higher in 1 and Republic of Moldova in 1.
Head to head by decade
| Decade | Azerbaijan | Republic of Moldova | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 99.09 | 96.53 | 2.56 | Azerbaijan |
| 2020s | 94.83 | 95.87 | 1.05 | Republic of Moldova |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Azerbaijan or Republic of Moldova?
- Republic of Moldova, at 96.4 against 96.11 in Azerbaijan as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Azerbaijan and Republic of Moldova?
- 0.29, with Republic of Moldova ahead.
- How many years of comparable data are there for Azerbaijan and Republic of Moldova?
- 5 years are reported by both, from 2017 to 2021.
- How do Azerbaijan and Republic of Moldova rank globally for the number of people with susceptibility test result for rifampicin?
- Azerbaijan ranks 47th and Republic of Moldova ranks 44th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.